Compare Neurocrine Biosciences Inc (NBIX) vs Vanguard Short Term Corporate Bond ETF (VCSH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Vanguard Short Term Corporate Bond ETF — how do they compare? Neurocrine Biosciences Inc trades at $142.6 (market cap $14.36B), while Vanguard Short Term Corporate Bond ETF trades at $77.28 (market cap $51.90B). The key difference: Vanguard Short Term Corporate Bond ETF is far larger — about 3.6× Neurocrine Biosciences Inc's market cap, and Neurocrine Biosciences Inc is trading nearer its 52-week high, Vanguard Short Term Corporate Bond ETF nearer its low. Which is the better fit depends on your goals.
| NBIX | VCSH | |
|---|---|---|
Market Cap | $14.36B | $51.90B |
Volume | 1,237,180 | 2,892,221 |
Sector | Health | Fixed Income |
52-Week High | $185.50 | $80.20 |
52-Week Low | $123.10 | $77.03 |
Typical Hold Time | 23 Days | — |
Enterprise Value | $14.37B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $141.69, down 1.24% on the day, with a bearish technical signal from moving averages. Fundamentally, the company shows strong profitability with a 20.91% net income margin and consistent earnings beats, including a significant Q2 2026 beat. Recent news highlights pipeline advancements and executive appointments, while analyst sentiment remains overwhelmingly positive.
The outlook for NBIX is supported by robust fundamentals and strong analyst buy ratings, but near-term price action is challenged by technical bearishness. Key opportunities include product diversification and pipeline growth, while risks involve execution of expansion plans and potential pricing pressures on key products like INGREZZA.
VCSH trades at $77.285 with minimal daily movement (+0.02%). The technical outlook is bearish with moving averages signaling caution, though oscillators remain neutral. Recent news highlights VCSH's competitive 4.5% dividend yield and low 0.03% expense ratio, positioning it as a stable income alternative to CDs or stable value funds. The fund's short 2.7-year duration minimizes interest rate risk, but credit spreads remain tight, limiting near-term upside potential.
VCSH offers conservative investors higher yields than traditional safe-harbor investments with minimal volatility. The primary risk involves corporate credit exposure during economic downturns, while the main opportunity lies in its attractive risk-adjusted returns for short-term bond allocations. Current market sentiment is neutral with some institutional rotation observed in recent filings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Vanguard Short Term Corporate Bond ETF
VCSH tracks the Bloomberg U.S. 1-5 Year Corporate Bond Index, focusing on high-quality, investment-grade debt with short maturities. It is designed to offer higher income than Treasury bills with significantly lower interest rate sensitivity than intermediate or long-term bond funds.
Read more on VCSH →
